Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication

AIDS Research and Human Retroviruses

Volumn 31, Issue 1, 2015, Pages 13-24

  Euler, Zelda ^a   Alter, Galit ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; MONOCLONAL ANTIBODY; VIRUS PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS; ARTICLE; CELL THERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE CONTROL; DRUG HALF LIFE; DRUG TARGETING; GENE MUTATION; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT PERIOD; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION; CD4+ T LYMPHOCYTE; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; VIROLOGY; VIRUS LATENCY;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4-POSITIVE T-LYMPHOCYTES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; VIRUS LATENCY;

EID: 84928557851     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0235     Document Type: Article

References (149)

1. Levy JA: Not an HIV cure, but encouraging new directions. N Engl J Med 2009;360(7):724-725
2. Saez-Cirion A, Bacchus C, Hocqueloux L, et al.: Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy: ANRS VISCONTI Study. PLoS Pathog 2013;9(3):e1003211
3. Hansen SG, Piatak M Jr, Ventura AB, et al.: Immune clearance of highly pathogenic SIV infection. Nature 2013; 502(7469):100-104
4. Ylisastigui L, Archin NM, Lehrman G, et al.: Coaxing HIV-1 from resting CD4 T cells: Histone deacetylase inhibition allows latent viral expression. AIDS 2004;18(8): 1101-1108
5. Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, et al.: Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 2013;9(5): 993-1001
6. Archin NM, Espeseth A, Parker D, et al.: Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009;25(2):207-212
7. Xing S, Bullen CK, Shroff NS, et al.: Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4 + T cell model without inducing global T cell activation. J Virol 2011;85(12):6060-6064
8. Zhu J, Gaiha GD, John SP, et al.: Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2012;2(4):807-816
9. Kulkosky J, Culnan DM, Roman J, et al.: Prostratin: Activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001;98(10): 3006-3015
10. Mehla R, Bivalkar-Mehla S, Zhang R, et al.: Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 2010;5(6):e11160
11. Kinter AL, Poli G, Maury W, et al.: Direct and cytokinemediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J Virol 1990;64(9):4306-4312
12. DeChristopher BA, Loy BA, Marsden MD, et al.: Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem 2012;4(9):705-710
13. Novis CL, Archin NM, Buzon MJ, et al.: Reactivation of latent HIV-1 in central memory CD4( + ) T cells through TLR-1/2 stimulation. Retrovirology. 2013;10:119
14. Archin NM, Liberty AL, Kashuba AD, et al.: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487(7408):482-485
15. Contreras X, Schweneker M, Chen CS, et al.: Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009;284(11):6782-6789
16. Matalon S, Palmer BE, Nold MF, et al.: The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4( + ) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr 2010;54(1): 1-9
17. Reuse S, Calao M, Kabeya K, et al.: Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: Implications for treatment of latent infection. PLoS One 2009;4(6):e6093
18. Choi BS, Lee HS, Oh YT, et al.: Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1. AIDS 2010;24(4):609-611
19. Yin H, Zhang Y, Zhou X, and Zhu H: Histone deacetylase inhibitor oxamflatin increases HIV-1 transcription by inducing histone modification in latently infected cells. Mol Biol Rep 2011;38(8):5071-5078
20. Cilo A, Sobolewski M, Bosch RJ, et al.: Only a small fraction of HIV-1 proviruses in resting CD4 + T cells can be induced to produce virions ex vivo with anti-CD3/ CD28 or vorinostat. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, Georgia. Abstract #371
21. Blazkova J, Chun TW, Belay BW, et al.: Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4( + ) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis 2012;206(5):765-769
22. Bullen CK, Laird GM, Durand CM, et al.: New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014;20(4):425-429
23. Cillo AR, Sobolewski MD, Bosch RJ, et al.: Quantification of HIV-1 latency reversal in resting CD4 + T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2014;111(19):7078-7083
24. Shan L, Deng K, Shroff NS, et al.: Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012;36(3):491-501
25. Deeks SG: HIV: Shock and kill. Nature 2012;487(7408): 439-440
26. Jain V, Hartogensis W, Bacchetti P, et al.: Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013;208(8):1202-1211
27. Strain MC, Little SJ, Daar ES, et al.: Effect of treatment, during primary infection on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005;191(9): 1410-1418
28. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al.: Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010;24(10): 1598-1601
29. Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al.: Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013;68(5):1169-1178
30. Buzon MJ, Martin-Gayo E, Pereyra F, et al.: Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol 2014;88(17):10056-10065
31. Grijsen ML, Steingrover R, Wit FW, et al.: No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: The randomized Primo-SHM trial. PLoS Med 2012;9(3):e1001196
32. Investigators ST, Fidler S, Porter K, et al.: Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368(3):207-217
33. Saez-Cirion A, Bacchus C, Hocqueloux L, et al.: Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy: ANRS VISCONTI Study. PLoS Pathog 2013;9(3):e1003211
34. Lisziewicz J, Rosenberg E, Lieberman J, et al.: Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999;340(21):1683-1684
35. Jessen H, Allen TM, and Streeck H: How a single patient influenced HIV research-15-year follow-up. N Engl J Med 2014;370(7):682-683
36. Garcia F, Leon A, Gatell JM, et al.: Therapeutic vaccines against HIV infection. Hum Vaccin Immunother 2012;8(5): 569-581
37. Garcia F, Climent N, Assoumou L, et al.: A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011;203(4):473-478
38. French AR and Yokoyama WM: Natural killer cells and viral infections. Curr Opin Immunol 2003;15(1):45-51
39. Jamieson AM, Diefenbach A, McMahon CW, et al.: The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17(1):19-29
40. Coudert JD, Zimmer J, Tomasello E, et al.: Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 2005; 106(5):1711-1717
41. Champsaur M and Lanier LL: Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010;235(1):267-285
42. Nolting A, Dugast AS, Rihn S, et al.: MHC class I chainrelated protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction. Virology 2010;406(1):12-20
43. Shibata-Koyama M, Iida S, Misaka H, et al.: Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 2009;37(3):309-321
44. Davies J, Jiang L, Pan LZ, et al.: Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 2001;74(4):288-294
45. Goede V, Fischer K, Busch R, et al.: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370(12):1101-1110
46. Chan AC and Carter PJ: Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010;10(5): 301-316
47. Checkley MA, Luttge BG, and Freed EO: HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 2011;410(4):582-608
48. Moore PL, Crooks ET, Porter L, et al.: Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006;80(5):2515-2528
49. Poignard P, Moulard M, Golez E, et al.: Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 2003;77(1):353-365
50. Bartesaghi A, Merk A, Borgnia MJ, et al.: Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol 2013;20(12):1352-1357
51. Lyumkis D, Julien JP, de Val N, et al.: Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013;342(6165):1484-1490
52. Guttman M, Garcia NK, Cupo A, et al.: CD4-induced activation in a soluble HIV-1 Env trimer. Structure 2014; 22(7):974-984
53. Veillette M, Desormeaux A, Medjahed H, et al.: Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol 2014;88(5):2633-2644
54. Banerjee K, Klasse PJ, Sanders RW, et al.: IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses 2010;26(4):445-458
55. Wren LH, Chung AW, Isitman G, et al.: Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 2013;138(2):116-123
56. Yamada T, Watanabe N, Nakamura T, and Iwamoto A: Antibody-dependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface. J Immunol 2004;172(4):2401-2406
57. Tiemessen CT, Shalekoff S, Meddows-Taylor S, et al.: Cutting edge: Unusual NK cell responses to HIV-1 peptides are associated with protection against maternalinfant transmission of HIV-1. J Immunol 2009;182(10): 5914-5918
58. Isitman G, Chung AW, Navis M, et al.: Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 2011;412(1):110-116
59. Pace MJ, Graf EH, Agosto LM, et al.: Directly infected resting CD4 + T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog 2012;8(7):e1002818
60. Kwong PD and Mascola JR: Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity 2012;37(3):412-425
61. Mouquet H: Antibody B cell responses in HIV-1 infection. Trends Immunol 2014;35(11):549-561
62. Pollara J, Bonsignori M, Moody MA, et al.: Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr HIV Res 2013;11(5):378-387
63. Scharf L, Scheid JF, Lee JH, et al.: Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 2014;7(3):785-795
64. Falkowska E, Le KM, Ramos A, et al.: Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014;40(5):657-668
65. Huang J, Kang BH, Pancera M, et al.: Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014;515(7525):138-142
66. Guan Y, Pazgier M, Sajadi MM, et al.: Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci USA 2013;110(1):E69-78
67. Ferrari G, Pollara J, Kozink D, et al.: An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibodydependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011;85(14):7029-7036
68. Chung AW, Navis M, Isitman G, et al.: Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol 2011;24(2):171-175
69. North TW, Higgins J, Deere JD, et al.: Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010;84(6):2913-2922
70. Svicher V, Ceccherini-Silberstein F, Antinori A, et al.: Understanding HIV compartments and reservoirs. Curr HIV/AIDS Rep 2014;11(2):186-194
71. Cory TJ, Schacker TW, Stevenson M, and Fletcher CV: Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS 2013;8(3):190-195
72. Maghazachi AA: Compartmentalization of human natural killer cells. Mol Immunol 2005;42(4):523-529
73. Coleman CM and Wu L: HIV interactions with monocytes and dendritic cells: Viral latency and reservoirs. Retrovirology 2009;6:51
74. Porter RR: Separation and isolation of fractions of rabbit gamma-globulin containing the antibody and antigenic combining sites. Nature 1958;182(4636):670-671
75. Jefferis R and Lund J: Interaction sites on human IgG-Fc for FcgammaR: Current models. Immunol Lett 2002; 82(1-2):57-65
76. Jefferis R: Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012;526(2):159-166
77. Jefferis R: Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8(3):226-234
78. Barouch DH, Whitney JB, Moldt B, et al.: Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013;503(7475):224-228
79. Klein F, Halper-Stromberg A, Horwitz JA, et al.: HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012;492(7427):118-122
80. Horwitz JA, Halper-Stromberg A, Mouquet H, et al.: HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci USA 2013; 110(41):16538-16543
81. Shingai M, Nishimura Y, Klein F, et al.: Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013;503(7475): 277-280
82. Halper-Stromberg A, Lu CL, Klein F, et al.: Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014;158(5):989-999
83. Dijstelbloem HM, van de Winkel JG, and Kallenberg CG: Inflammation in autoimmunity: Receptors for IgG revisited. Trends Immunol 2001;22(9):510-516
84. Dugast AS, Tonelli A, Berger CT, et al.: Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 2011;415(2):160-167
85. Brier AM, Chess L, and Schlossman SF: Human antibodydependent cellular cytotoxicity. Isolation and identification of a subpopulation of peripheral blood lymphocytes which kill antibody-coated autologous target cells. J Clin Invest 1975;56(6):1580-1586
86. Meguro H, Kervina M, and Wright PF: Antibody-dependent cell-mediated cytotoxicity against cells infected with respiratory syncytial virus: Characterization of in vitro and in vivo properties. J Immunol 1979;122(6):2521-2526
87. Koup RA, Robinson JE, Nguyen QV, et al.: Antibodydependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS 1991;5(11):1309-1314
88. Jenkins M, Mills J, and Kohl S: Natural killer cytotoxicity and antibody-dependent cellular cytotoxicity of human immunodeficiency virus-infected cells by leukocytes from human neonates and adults. Pediatr Res 1993;33(5):469-474
89. Kramski M, Parsons MS, Stratov I, and Kent SJ: HIVspecific antibody immunity mediated through NK cells and monocytes. Curr HIV Res 2013;11(5):388-406
90. Sips M, Sciaranghella G, Diefenbach T, et al.: Altered distribution of mucosal NK cells during HIV infection. Mucosal Immunol 2012;5(1):30-40
91. Kramski M, Parsons MS, Stratov I, and Kent SJ: HIVspecific antibody immunity mediated through NK cells and monocytes. Curr HIV Res 2013;11(5):388-406
92. Yoneto T, Waki S, Takai T, et al.: A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection. J Immunol 2001;166(10):6236-6241
93. Ackerman ME, Dugast AS, McAndrew EG, et al.: Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcgammaR2a and FcgammaR2b. J Virol 2013;87(10):5468-5476
94. Huber VC, Lynch JM, Bucher DJ, et al.: Fc receptormediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001; 166(12):7381-7388
95. Indik Z, Kelly C, Chien P, et al.: Human Fc gamma RII, in the absence of other Fc gamma receptors, mediates a phagocytic signal. J Clin Invest 1991;88(5):1766-1771
96. Lustig HJ and Bianco C: Antibody-mediated cell cytotoxicity in a defined system: Regulation by antigen, antibody, and complement. J Immunol 1976;116(1):253-260
97. Montefiori DC, Murphey-Corb M, Desrosiers RC, and Daniel MD: Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. J Virol 1990;64(10):5223-5225.
98. Ravetch JV and Clynes RA: Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998; 16:421-432
99. Speth C, Stoiber H, and Dierich MP: Complement in different stages of HIV infection and pathogenesis. Int Arch Allergy Immunol 2003;130(4):247-257
100. Mishima Y, Terui Y, Kuniyoshi R, et al.: High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcgammaRllla polymorphism. Int Immunol 2012;24(8): 477-483
101. Wang SY, Veeramani S, Racila E, et al.: Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009;114(26):5322-5330
102. Idusogie EE, Wong PY, Presta LG, et al.: Engineered antibodies with increased activity to recruit complement. J Immunol 2001;166(4):2571-2575
103. Di Gaetano N, Cittera E, Nota R, et al.: Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171(3):1581-1587
104. Reichert JM: Antibodies to watch in 2014: Mid-year update. MAbs 2014;6(4):799-802
105. Golay J, Manganini M, Facchinetti V, et al.: Rituximabmediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003;88(9):1002-1012
106. DallOzzo S, Tartas S, Paintaud G, et al.: Rituximabdependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64(13):4664-4669
107. Cartron G, Dacheux L, Salles G, et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99(3):754-758
108. Bibeau F, Lopez-Crapez E, Di Fiore F, et al.: Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27(7):1122-1129
109. Mellor JD, Brown MP, Irving HR, et al.: A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 2013;6:1
110. Tamura K, Shimizu C, Hojo T, et al.: FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011; 22(6):1302-1307
111. Natsume A, Wakitani M, Yamane-Ohnuki N, et al.: Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J Immunol Methods 2005;306(1-2):93-103
112. Niwa R, Natsume A, Uehara A, et al.: IgG subclassindependent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005;306(1-2):151-160
113. Niwa R, Sakurada M, Kobayashi Y, et al.: Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005;11(6):2327-2336
114. Shields RL, Lai J, Keck R, et al.: Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002;277(30):26733-26740
115. Shinkawa T, Nakamura K, Yamane N, et al.: The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278(5):3466-3473
116. Zeitlin L, Pettitt J, Scully C, et al.: Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci USA 2011;108(51):20690-20694
117. Nimmerjahn F, Bruhns P, Horiuchi K, and Ravetch JV: FcgammaRIV: A novel FcR with distinct IgG subclass specificity. Immunity 2005;23(1):41-51
118. Nimmerjahn F and Ravetch JV: Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005;310(5753):1510-1512
119. Lux A and Nimmerjahn F: Of mice and men: The need for humanized mouse models to study human IgG activity in vivo. J Clin Immunol 2013;33(Suppl 1):S4-8
120. Jefferis R: Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012;526(2):159-166
121. Parren PW, Warmerdam PA, Boeije LC, et al.: On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 1992;90(4):1537-1546
122. Morell A, Terry WD, and Waldmann TA: Metabolic properties of IgG subclasses in man. J Clin Invest 1970; 49(4):673-680
123. Salfeld JG: Isotype selection in antibody engineering. Nat Biotechnol 2007;25(12):1369-1372
124. van Egmond M and Bakema JE: Neutrophils as effector cells for antibody-based immunotherapy of cancer. Semin Cancer Biol 2013;23(3):190-199
125. Guettinger Y, Barbin K, Peipp M, et al.: A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells. J Immunol 2010;184(3):1210-1217
126. Deo YM, Sundarapandiyan K, Keler T, et al.: Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cellmediated cytotoxicity of tumor targets in whole blood. J Immunol 1998;160(4):1677-1686
127. Chung AW, Ghebremichael M, Robinson H, et al.: Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 2014;6(228):228ra238
128. Tomaras GD, Yates NL, Liu P, et al.: Initial B-cell responses to transmitted human immunodeficiency virus type 1: Virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82(24):12449-12463
129. Lux A and Nimmerjahn F: Impact of differential glycosylation on IgG activity. Adv Exp Med Biol 2011;780: 113-124
130. Shikata K, Yasuda T, Takeuchi F, et al.: Structural changes in the oligosaccharide moiety of human IgG with aging. Glycoconj J 1998;15(7):683-689
131. Ackerman ME, Crispin M, Yu X, et al.: Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest 2013;123(5):2183-2192
132. Moore JS, Wu X, Kulhavy R, et al.: Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS 2005;19(4):381-389
133. Hessell AJ, Hangartner L, Hunter M, et al.: Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007;449(7158):101-104
134. Moldt B, Shibata-Koyama M, Rakasz EG, et al.: A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012;86(11): 6189-6196
135. Wira CR, Fahey JV, Sentman CL, et al.: Innate and adaptive immunity in female genital tract: Cellular responses and interactions. Immunol Rev 2005;206:306-335
136. Chung AW, Crispin M, Pritchard L, et al.: Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. AIDS 2014;28(17): 2523-2530
137. Richards JO, Karki S, Lazar GA, et al.: Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008;7(8): 2517-2527
138. Lazar GA, Dang W, Karki S, et al.: Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006;103(11):4005-4010
139. Moore GL, Chen H, Karki S, and Lazar GA: Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010; 2(2):181-189
140. Moldt B, Schultz N, Dunlop DC, et al.: A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcgamma receptors to define the role of effector functions in protection against HIV. J Virol 2011;85(20): 10572-10581
141. Roopenian DC and Akilesh S: FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7(9):715-725
142. Lobo ED, Hansen RJ, and Balthasar JP: Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93(11):2645-2668
143. Kubota T, Niwa R, Satoh M, et al.: Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009;100(9):1566-1572
144. Stapleton NM, Andersen JT, Stemerding AM, et al.: Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2011;2:599
145. Denton PW, Long JM, Wietgrefe SW, et al.: Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 2014;10(1):e1003872
146. Nisonoff A and Mandy WJ: Quantitative estimation of the hybridization of rabbit antibodies. Nature 1962;194:355-359
147. Staerz UD, Kanagawa O, and Bevan MJ: Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314(6012):628-631
148. Linke R, Klein A, and Seimetz D: Catumaxomab: Clinical development and future directions. MAbs 2010;2(2):129-136
149. Hatano H, Jain V, Hunt PW, et al.: Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4 + T cells. J Infect Dis 2013;208(1):50-56